Login to Your Account

XenoPort in the Storm: GSK Split Ends Horizant Squabble

By Randy Osborne
Staff Writer

Monday, November 12, 2012
It wasn't the first time that a deal by GlaxoSmithKline plc left Wall Street unsatisfied and ultimately fizzled, but the severing of XenoPort's tie with the pharma giant leaves the biotech in fairly good shape: full rights to Horizant (gabapentin enacarbil) and $20 million in new equity money.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription